← Browse by Condition
Medical Condition

myxomatous mitral valve degeneration

Total Trials
1
Recruiting Now
1
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for myxomatous mitral valve degeneration sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myxomatous mitral valve degeneration Clinical Trials

How many clinical trials are currently recruiting for myxomatous mitral valve degeneration?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for myxomatous mitral valve degeneration, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for myxomatous mitral valve degeneration?
myxomatous mitral valve degeneration research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a myxomatous mitral valve degeneration clinical trial?
Eligibility criteria for myxomatous mitral valve degeneration trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
IRCCS Policlinico S. Donato 1 trial

Recruiting Clinical Trials

NCT07384871
Recruiting
AI-Based Shape and Function Analysis of Mitral Valve Prolapse Using 3D Ultrasound
Enrollment
150 pts
Location
Italy
Sponsor
IRCCS Policlinico S. Donato
View Trial →

Related Conditions

mitral valve prolapse (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology